Ultragenyx Pharmaceutical Inc RARE:NASDAQ

Last Price$59.66NASDAQ Closing Price as of 4:00PM ET 6/30/22

Today's Change-0.58(0.96%)
Bid (Size)$42.42 (1)
Ask (Size)$95.77 (1)
Day Low / High$58.14 - 60.24
Volume656.6 K
 

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/30/2022

 

Ultragenyx Pharmaceutical Inc ( NASDAQ )

Price: $59.66
Change: -0.58 (0.96%)
Volume: 656.6 K
4:00PM ET 6/30/2022
 
 

Cytokinetics Inc ( NASDAQ )

Price: $39.29
Change: -9.45 (19.39%)
Volume: 10.4 M
4:00PM ET 6/30/2022
 
 

Turning Point Therapeutics Inc ( NASDAQ )

Price: $75.25
Change: -0.05 (0.07%)
Volume: 1.1 M
4:00PM ET 6/30/2022
 
 

Karuna Therapeutics Inc ( NASDAQ )

Price: $126.51
Change: +1.53 (1.22%)
Volume: 410.5 K
4:00PM ET 6/30/2022
 
 

Mirati Therapeutics Inc ( NASDAQ )

Price: $67.13
Change: -0.11 (0.16%)
Volume: 679.3 K
4:00PM ET 6/30/2022
 

Read more news Recent News

Goldman Sachs Adjusts Price Target for Ultragenyx Pharmaceutical to $101 From $139, Keeps Neutral Rating
11:18AM ET 5/24/2022 MT Newswires

Ultragenyx Pharmaceutical (RARE) has an average buy rating among analysts, with a price target range of $73 to $162. (MT Newswires covers equity, commodity...

Piper Sandler Adjusts Price Target on Ultragenyx Pharmaceutical to $135 From $170, Reiterates Overweight Rating
8:01AM ET 5/19/2022 MT Newswires

Ultragenyx Pharmaceutical (RARE) has an average rating of outperform and price targets ranging from $71 to $186, according to analysts polled by Capital...

Ultragenyx Pharmaceutical Licenses Abeona Therapeutics' Sanfilippo Syndrome Type A Therapy
10:57AM ET 5/17/2022 MT Newswires

Ultragenyx Pharmaceutical (RARE) and Abeona Therapeutics (ABEO) said Tuesday they have entered into an exclusive license agreement for ABO-102, or UX111, a...

Citigroup Adjusts Price Target on Ultragenyx Pharmaceutical to $146 From $150, Reiterates Buy Rating
7:32AM ET 5/10/2022 MT Newswires

Ultragenyx Pharmaceutical (RARE) has an average rating of outperform and price targets ranging from $71 to $186, according to analysts polled by Capital...

Company Profile

Business DescriptionUltragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010, and is headquartered in Novato, CA. View company web site for more details
Address60 Leveroni Court
Novato, California 94949
Phone+1.415.483.8800
Number of Employees610
Recent SEC Filing06/29/20224
President, Chief Executive Officer & DirectorEmil D. Kakkis
Chief Financial Officer & Executive Vice PresidentMardi C. Dier
Chief Technical Operations Officer & Senior VPDennis Karl Huang
Chief Scientific OfficeSamuel C. Wadsworth

Company Highlights

Price Open$59.41
Previous Close$60.24
52 Week Range$45.20 - 104.38
Market Capitalization$4.2 B
Shares Outstanding69.9 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/01/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$6.55
Beta vs. S&P 500N/A
Revenue$51.5 M
Net Profit Margin-141.65%
Return on Equity-51.89%

Analyst Ratings as of 04/20/2022

Buy
13
Overweight
1
Hold
4
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset